Why the study?
Does standard cardiac therapy improve late doxorubicin-induced cardiomyopathy?
Does standard cardiac therapy improve late doxorubicin-induced cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Late doxorubicin-induced cardiomyopathy may be reversible and responsive to standard cardiac therapy, challenging the previous belief that it is rapidly progressive and unresponsive.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Murray Cohen (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: